We are in the midst of an epidemic of diabetes, and the prevalence appears to be especially marked within Delaware. To prevent tragic long-term complications of diabetes, and to minimize the enormous costs associated with treating them, an emphasis must be placed on the early diagnosis and aggressive management of diabetes. The changes in the classification, diagnosis and screening for diabetes should help to redirect the focus to one of preventive care.

Delaware↗

PubMed1998

Intravenous insulin infusion therapies for postoperative coronary artery bypass graft patients.

BACKGROUND: Hyperglycemia is very common in postoperative coronary artery bypass graft patients. Although sliding scale insulin therapy is often used, there is no standard of care for the management of hyperglycemia. METHODS: Different intravenous insulin therapies were used in three consecutive sets of hyperglycemic postoperative coronary artery bypass graft patients. The first method was a sliding scale intravenous insulin regimen beginning with four units/hr, and increasing by four units/hr each hourly bedside arterial whole blood glucose measurement greater than 250 mg/dL (13.9 mmol/L) (n = 58). The second and third methods were constant insulin infusions at a rate of eight units (n = 60) and 20 units/hr (n = 51) respectively. Insulin infusions were reduced to two units/hr when the glucose concentration decreased to 150-250 mg/dL (8.3-13.9 mmol/L), and was stopped when it fell below 150 mg/dL (8.3 mmol/L). RESULTS: Thirty percent of patients undergoing coronary artery bypass grafting had a diagnosis of diabetes mellitus. Forty-eight percent of all patients had a glucose value greater than 250 mg/dL (13.9 mmol/L) within the first 24 hours postoperatively. The three intravenous insulin infusion regimens produced similar control of arterial whole blood glucose concentrations. Patients with high initial glucose concentrations (greater than 400 mg/dL) (22.2 mmol/L) required intravenous insulin therapy for ten or more hours before attaining the target range of 151-250 mg/dL (8.3-13.9 mmol/L). CONCLUSIONS: Constant-rate intravenous insulin therapy is effective in lowering arterial whole blood glucose concentrations in postoperative coronary artery bypass graft patients. Initiation of intravenous insulin therapy at lower glucose values reduces the time necessary for the infusion.

Coronary Artery Bypass↗

PubMed1998

The FDA and drug safety.

Explore the source record for details and available documents.

Drug Approval↗

PubMed1998

Assisted living.

Explore the source record for details and available documents.

Aged↗

PubMed1997

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.

The potential for eprosartan, a nonbiphenyl tetrazole angiotensin II receptor antagonist, to affect the 24-hour plasma glucose profiles in type II diabetic patients treated with glyburide was investigated in this randomized, placebo-controlled, double-blind (eprosartan-placebo phase only), two-period, period-balanced, crossover study. All patients received a stable oral dose (3.75-10 mg/day) of glyburide for at least 30 days before the first dose of double-blind study medication was administered. Patients were randomized to receive either 200-mg oral doses of eprosartan twice daily or matching oral placebo doses concomitantly with glyburide for 7 days during each treatment period. After a minimum washout period of 14 days, patients were crossed over to the alternate treatment. Serial samples to measure glucose concentrations in plasma were collected over a 24-hour period on the day before administration of eprosartan or placebo and again on day 7. Mean glucose concentrations were comparable between treatment groups before administration of eprosartan or placebo. The point estimate (90% confidence interval) for the ratio of the average mean 24-hour plasma glucose concentrations of eprosartan + glyburide to placebo + glyburide after 7 days of administration was 0.96 (0.90, 1.01). Eprosartan did not significantly alter the 24-hour plasma glucose profile in patients with type II diabetes mellitus who were previously stabilized on glyburide.

Acrylates↗

PubMed1997

Vibratory thresholds correlation with systolic blood pressure in diabetic women.

Previous studies have suggested a potential association of elevated blood pressure (BP) and the development of diabetic neuropathy for individuals with insulin-dependent diabetes mellitus. In this study, we examined an association between BP and vibratory thresholds (assessment modality of large sensory nerve fiber function) for 33 participants with non-insulin-dependent diabetes mellitus. There were 19 women and 14 men aged 58 +/- 7 (mean +/- SD) years, with diabetes duration of 7 +/- 6 years and a body mass index of 29 +/- 5 kg/m2. None of the individuals were taking any medications that lower BP and all were negative for the presence of microalbuminuria. Vibratory thresholds were determined at three visits using a two-alternative, forced-choice procedure. BP was assessed by 24-h ambulatory BP monitoring. As expected, vibratory thresholds were higher for men than for women (6.3 +/- 4 v 4.2 +/- 3 vibration units) but there was no statistical difference after controlling for height. In multivariate analyses with vibratory thresholds as the dependent variable, duration of diabetes (P < 0.01), age (P < .01) and systolic BP (SBP) (P < .01) explained approximately 70% of the overall variability of the gender-specific (ie, female) model. The variability was similar (ie, 70% to 73%) no matter which SBP measure was available for modeling. In terms of diastolic blood pressure (DBP) measures, only the percentage of abnormal readings (ie, > 90 mm Hg) for day DBP was found to be independently associated with vibratory thresholds for women. The association of BP and large sensory nerve fiber dysfunction for nonnephropathic diabetic women found in this cross-sectional study warrants further investigation.

Blood Pressure↗

PubMed1997

A cross-sectional study comparing two quantitative sensory testing devices in individuals with diabetes.

OBJECTIVE: This study was designed to compare circumference discrimination thresholds, as assessed by the Tacticon (Tacticon, Inc., Westtown, PA), a new quantitative sensory testing (QST) device, with vibratory thresholds, an assessment modality of large sensory nerve fibers, in individuals with diabetes. RESEARCH DESIGN AND METHODS: In this study, 150 individuals with diabetes were evaluated. Vibratory thresholds and circumference discrimination thresholds, evaluated with the Tacticon, were determined using a two-alternative forced-choice procedure. RESULTS: Vibratory thresholds increased with decreasing ability to discriminate differences in circumference (P < 0.001) for those below and above 50 years of age. Agreement between the two QST devices was assessed via the kappa-statistic in both age-groups (i.e., < or = 50 years old [kappa = 0.67], > 50 years old [kappa = 0.55]). In multiple logistic regression, where circumference discrimination thresholds were the dependent variable, age, duration of diabetes, and height were found to be independently associated for those > 50 years old. CONCLUSIONS: The Tacticon offers a simple method of assessing the complex function of area discrimination. Our results suggest that the Tacticon can detect neuropathy in the primary care setting. Its cost, portability, and ease of use provide some advantages over existing QST equipment.

Adult↗

PubMed1997

Computer systems for hospitals and integrated health systems.

Explore the source record for details and available documents.

Confidentiality↗

PubMed1996

Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease.

The CRH test may sometimes be useful in the differential diagnosis of Cushing's syndrome, because most patients with pituitary ACTH-dependent Cushing's syndrome (Cushing's disease) respond to CRH, but those with other causes of Cushing's syndrome usually do not. However, about 10% of Cushing's disease patients fail to respond to CRH. We wondered if we could eliminate these false negative results either by exploiting the potential additive or synergistic effects of another ACTH secretagogue or by reducing glucocorticoid inhibition of CRH's ACTH-releasing effect. We compared the effect on plasma ACTH and cortisol in 51 patients with Cushing's disease of administering ovine CRH (1 microgram/kg BW, i.v.) alone, arginine vasopressin (AVP; 10 U, i.m.) alone, the combination of CRH and AVP, and CRH after pretreatment with metyrapone (1 g, orally, every 4 h for three doses; CRH + MET). The rates of nonresponse (ACTH increment, < 35%; cortisol increment, < 20%) to AVP and CRH alone were 26% and 8%, respectively; all patients responded to CRH + AVP. The lack of response was not due to improper administration or rapid metabolism of the agonist, because plasma CRH and AVP concentrations were similar in responders and nonresponders. A synergistic ACTH response to CRH + AVP occurred in 65% of the patients. MET pretreatment increased basal plasma ACTH levels in most patients and induced the greatest mean peak ACTH response to CRH, but 8% of the patients did not respond to CRH + MET with an ACTH increment of 35% or more. Because all of the Cushing's disease patients tested in this study responded to the combination of CRH + AVP, whereas 8% failed to respond to CRH alone, we conclude that CRH + AVP administration may provide a more reliable test for the differential diagnosis of ACTH-dependent Cushing's syndrome than administration of CRH alone. Whether this improved sensitivity is accompanied by unaltered specificity for Cushing's disease must be tested in patients with chronic ectopic ACTH syndrome.

Adolescent↗

PubMed1996

Glucose monitoring of patients with diabetes mellitus receiving general anesthesia: a study of the practices of anesthesia providers in a large community hospital.

Surgical stress causes hyperglycemia with potential complications (e.g., impaired granulocytic function and delayed wound healing) particularly when glucose levels exceed 250 mg/dL. Standards of care for patients with diabetes undergoing surgery may vary by geographic locale, type of surgical procedure, and type of diabetes. We explored whether anesthesia providers monitor glucose levels in patients with diabetes. Records of 100 patients with diabetes who underwent surgery under general anesthesia (length of procedure: range, 1.9-11.8 hours) were reviewed. Demographic information, glucose levels, frequency of glucose monitoring, and treatment used for diabetes management preoperatively, intraoperatively, and postoperatively were recorded. There were 46 males and 54 females, aged 62 +/- 13 years (55% currently treated with insulin). Of the study cohort, 89% had preoperative, 23% had intraoperative, and 54% had postoperative glucose monitoring performed. As expected, postoperative glucose concentrations were significantly higher than preoperative glucose levels (mean difference, 99 mg/dL, P < .01). The mean postoperative glucose level was 262 +/- 89 mg/dL with 30 of the 54 monitored patients having a postoperative glucose level greater than 250 mg/dL. Individuals treated with insulin and those who underwent major surgery were more likely to have glucose levels monitored. These results suggest that better strategies for monitoring glucose levels during the surgical period are needed.

Aged↗

PubMed1995

A comparison between alternative and trade name glucose test strips.

OBJECTIVE: To determine the reliability of seven different alternative glucose test strips manufactured for use with three different glucose meters. RESEARCH DESIGN AND METHODS: Venous blood samples were obtained from volunteers to test trade name glucose test strips on the manufacturers' glucose meters (One Touch II, Glucometer II, and Glucometer III), and the remainder of each sample was used for laboratory determination of blood glucose levels. In addition to the trade name test strips, Quick Check and First Choice test strips were tested on all meters, and Biotel test strips were also tested on the Glucometer III. RESULTS: In linear regression analysis, the R2 ranged from 0.84 to 0.97 for the test strips compared with plasma glucose values. The test strips with the highest accuracy and precision at all ranges of blood glucose levels were the One Touch II and Glucometer III trade name strips and the Quick Check and First Choice alternative strips for the One Touch II glucose meter and the First Choice alternative strip for the Glucometer II. Subgroup analysis based on ranges of blood glucose values, however, revealed that the alternative strips were not as accurate as the trade name test strips, with the exception of the First Choice alternative test strip for the Glucometer II. All of the trade name test strips were more precise than the alternative test strips designed for the individual meters. CONCLUSIONS: Alternative glucose test strips can be used to predict the actual laboratory blood glucose values but are generally not as accurate or precise as the trade name test strips.

Blood Glucose↗

PubMed1994

Use of arterial blood with bedside glucose reflectance meters in an intensive care unit: are they accurate?

OBJECTIVE: To compare blood glucose values obtained from two different sampling sites (arterial catheter and capillary from finger puncture), which were analyzed by a bedside reflectance meter. A sample was also analyzed by standard methods (oxygen electrode oxidation in the laboratory). DESIGN: Prospective, cross-sectional clinical study. SETTING: Cardiovascular intensive care unit (ICU) designed for postoperative open-heart surgery patients in a 1,100-bed medical center. PATIENTS: Sequential sample of 50 patients immediately after open-heart surgery. MEASUREMENTS AND MAIN RESULTS: The blood glucose concentration of each patient was analyzed on the patient's arrival to the ICU (immediately postoperatively) by three methods: one blood specimen was obtained from an arterial catheter, divided and analyzed either at the bedside by a reflectance meter (glucose method 1) or in the hospital laboratory (glucose method 2); another sample was obtained by lancing the fingertip and the glucose concentration was analyzed at the bedside in the same reflectance meter (glucose method 3). Using paired analyses to compare the mean glucose values of the bedside arterial whole blood sample (method 1) with the arterial serum sample (method 2) demonstrated that the glucose concentration in the arterial whole blood sample (method 1) was significantly (p < .001) higher. For 46 of 50 comparisons, the glucose value in the arterial whole blood sample (method 1) was higher, with a mean difference of 30 mg/dL (1.7 mmol/L). Although the mean difference was reduced to 10 mg/dL (0.6 mmol/L) when the arterial whole blood sample (method 1) was corrected for the hematocrit (i.e., < 35% [< 0.35]), the mean glucose concentration in the arterial whole blood samples (method 1) remained statistically higher (p < .05). The glucose concentration in the arterial serum sample (method 2) was significantly higher than the value determined from the bedside capillary sample (method 3) before (p < .05) and after (p < .001) correction for hematocrit. The difference in mean glucose concentrations between the arterial serum sample (method 2) and bedside capillary sample (method 3) was 9 mg/dL (0.5 mmol/L) when the capillary specimen (method 3) was not corrected for hematocrit. This difference increased to 21 mg/dL (1.2 mmol/L) when low hematocrit values were considered and appropriate adjustments of the glucose values were made. At the bedside, one can accurately correct arterial whole blood glucose values to correspond to laboratory values by the following formula: (0.94 x arterial whole blood glucose) + (4.6 x hematocrit) + (-16.5 x [37 degrees C--patient's temperature])--132 = laboratory glucose value. CONCLUSIONS: Since arterial whole blood samples give higher glucose results than arterial serum, the use of arterial whole blood in combination with reflectance meters must be recommended with caution. This caution is especially advised if the glucose values obtained with arterial whole blood are used in conjunction with a sliding scale of insulin, which depends on threshold concentrations of glucose. In our hospital, use of arterial whole blood in combination with reflectance meters could have resulted in an incorrect dose of insulin in 31 of 50 patients.

Adult↗

PubMed1993

The effects of age and diabetes mellitus on nerve function.

OBJECTIVE: This project evaluated the association of age and vibratory thresholds (assessment modality of large sensory nerve fibers) in subjects with and without diabetes mellitus. DESIGN: Cross-sectional study. SETTING: Medical Research Institute of Delaware. PARTICIPANTS: Individuals with non-insulin-dependent diabetes mellitus and non-diabetic control subjects. MEASUREMENTS: Vibratory thresholds were examined in four age groups (ie, < 45 yrs, 45-54 yrs, 55-64 yrs, > or = 65 yrs). The independent association of age, duration of diabetes, height, gender, glycemic control, and smoking history were analyzed in terms of their relationship to vibratory thresholds. MAIN RESULTS: Vibratory thresholds increased with age for both control and diabetic subjects. Comparing controls with diabetic subjects in the same age categorizes revealed significant differences for vibratory thresholds only in the > or = 65 year old age group. Modeling with vibratory thresholds as the dependent variable showed that age and male gender were independently associated with vibratory thresholds for the controls and explained the majority of the variability (R2 = 0.79). Age, duration of diabetes, and height were independently associated with vibratory thresholds for the diabetic subjects but explained much less of the variability (R2 = 0.39). CONCLUSIONS: The results suggest an acceleration of the natural aging process for large sensory nerve fiber function in diabetic subjects. Thus, young diabetic subjects may be at a risk of lower extremity complications as a result of injuries similar to that older non-diabetic individuals.

Adult↗